BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Targher G, Corey KE, Byrne CD. NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. Diabetes Metab 2021;47:101215. [PMID: 33296704 DOI: 10.1016/j.diabet.2020.101215] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
Number Citing Articles
1 Leow YW, Chan WK, Goh GB, Wong VW, Fan JG, Kim YS, Kim SU, Nakajima A, Seto WK, Lee IC, Huang YH, Kim YJ, Young JJ, Chow WC. Hepatic steatosis and metabolic risk factors among patients with chronic hepatitis B: The multicentre, prospective CAP-Asia study. J Viral Hepat 2023;30:319-26. [PMID: 36606597 DOI: 10.1111/jvh.13796] [Reference Citation Analysis]
2 Simon TG, Roelstraete B, Alkhouri N, Hagström H, Sundström J, Ludvigsson JF. Cardiovascular disease risk in paediatric and young adult non-alcoholic fatty liver disease. Gut 2023;72:573-80. [PMID: 36522149 DOI: 10.1136/gutjnl-2022-328105] [Reference Citation Analysis]
3 Kang MK, Kim MC. Clinical Implications of Cardiac Symptoms and Electrocardiographic Abnormalities for Advanced Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Medicina (Kaunas) 2023;59. [PMID: 36837575 DOI: 10.3390/medicina59020375] [Reference Citation Analysis]
4 Anastasiou G, Liberopoulos E, Petkou E, Koutsogianni AD, Adamidis PS, Liamis G, Ntzani E, Barkas F. Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin-Therapy: A 6-Year Retrospective Study. Diagnostics (Basel) 2023;13. [PMID: 36766607 DOI: 10.3390/diagnostics13030503] [Reference Citation Analysis]
5 Pipitone RM, Ciccioli C, Infantino G, La Mantia C, Parisi S, Tulone A, Pennisi G, Grimaudo S, Petta S. MAFLD: a multisystem disease. Ther Adv Endocrinol Metab 2023;14:20420188221145549. [PMID: 36726391 DOI: 10.1177/20420188221145549] [Reference Citation Analysis]
6 Fu H, Yu H, Zhao Y, Chen J, Liu Z. Association Between Hypertension and the Prevalence of Liver Steatosis and Fibrosis.. [DOI: 10.21203/rs.3.rs-2400318/v1] [Reference Citation Analysis]
7 Guo J, Wang P, Cui Y, Hu X, Chen F, Ma C. Alleviation Effects of Microbial Metabolites from Resveratrol on Non-Alcoholic Fatty Liver Disease. Foods 2022;12. [PMID: 36613310 DOI: 10.3390/foods12010094] [Reference Citation Analysis]
8 Fan H, Xu C, Li W, Huang Y, Hua R, Xiong Y, Yang Y, Feng X, Wang Z, Yuan Z, Zhou J. Ideal Cardiovascular Health Metrics Are Associated with Reduced Severity of Hepatic Steatosis and Liver Fibrosis Detected by Transient Elastography. Nutrients 2022;14. [PMID: 36558503 DOI: 10.3390/nu14245344] [Reference Citation Analysis]
9 Shatta MA, El-derany MO, Gibriel AA, El-mesallamy HO. Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro. Mol Cell Biochem 2022. [DOI: 10.1007/s11010-022-04619-6] [Reference Citation Analysis]
10 de Freitas LBR, Longo L, Filippi-Chiela E, de Souza VEG, Behrens L, Pereira MHM, Leonhard LC, Zanettini G, Pinzon CE, Luchese E, Lima GJSP, Cerski CT, Uribe-Cruz C, Álvares-da-Silva MR. Ornithine Aspartate and Vitamin-E Combination Has Beneficial Effects on Cardiovascular Risk Factors in an Animal Model of Nonalcoholic Fatty Liver Disease in Rats. Biomolecules 2022;12. [PMID: 36551202 DOI: 10.3390/biom12121773] [Reference Citation Analysis]
11 Xie F, Xu H, Zhang J, Liu X, Kou B, Cai M, Wu J, Dong J, Meng Q, Wang Y, Chen D, Zhang Y. Dysregulated hepatic lipid metabolism and gut microbiota associated with early-stage NAFLD in ASPP2-deficiency mice. Front Immunol 2022;13. [DOI: 10.3389/fimmu.2022.974872] [Reference Citation Analysis]
12 Heebøll S, Risikesan J, Ringgaard S, Kumarathas I, Sandahl TD, Grønbæk H, Søndergaard E, Nielsen S. Impaired Glucagon-Mediated Suppression of VLDL-Triglyceride Secretion in Individuals With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). Diabetes 2022;71:2402-11. [PMID: 36001750 DOI: 10.2337/db22-0313] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Lee S, Baek S, Lee Y, Kim T, Yim J, Son J, Kim H, Kang K, Kim JH, Rhee MH, Park S, Choi S, Park J. Ginsenoside Rg3-enriched Korean red ginseng extract attenuates Non-Alcoholic Fatty Liver Disease by way of suppressed VCAM-1 expression in liver sinusoidal endothelium. Journal of Ginseng Research 2022. [DOI: 10.1016/j.jgr.2022.10.005] [Reference Citation Analysis]
14 Zaman CF, Sultana J, Dey P, Dutta J, Mustarin S, Tamanna N, Roy A, Bhowmick N, Khanam M, Sultana S, Chowdhury S, Khanam F, Sakibuzzaman M, Dutta P. A Multidisciplinary Approach and Current Perspective of Nonalcoholic Fatty Liver Disease: A Systematic Review. Cureus 2022. [DOI: 10.7759/cureus.29657] [Reference Citation Analysis]
15 Rogalski JK, Subdys A, Gawlik-kotelnicka OE. The development of the Metabolic-associated Fatty Liver Disease during pharmacotherapy of mental disorders - a review. Current Problems of Psychiatry 2022;0. [DOI: 10.2478/cpp-2022-0013] [Reference Citation Analysis]
16 Song Q, Liu S, Ling Q, Gao Q, Yang R, Chen S, Wu S, Chen M, Cai J. Severity of Nonalcoholic Fatty Liver Disease is Associated With Cardiovascular Outcomes in Patients With Prehypertension or Hypertension: A Community–Based Cohort Study. Front Endocrinol 2022;13:942647. [DOI: 10.3389/fendo.2022.942647] [Reference Citation Analysis]
17 Ng CH, Wong ZY, Chew NWS, Chan KE, Xiao J, Sayed N, Lim WH, Tan DJH, Loke RWK, Tay PWL, Yong JN, Kong G, Huang DQ, Wang J, Chan M, Dalakoti M, Tamaki N, Noureddin M, Siddiqui MS, Sanyal AJ, Muthiah M. Hypertension is prevalent in non-alcoholic fatty liver disease and increases all-cause and cardiovascular mortality. Front Cardiovasc Med 2022;9. [DOI: 10.3389/fcvm.2022.942753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Cazac GD, Lăcătușu CM, Mihai C, Grigorescu ED, Onofriescu A, Mihai BM. New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis. Life (Basel) 2022;12:1189. [PMID: 36013368 DOI: 10.3390/life12081189] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 McPherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN, Cacciottolo TM, Goldin RD, Hallsworth K, Hebditch V, Jack K, Jarvis H, Johnson J, Li W, Mansour D, McCallum M, Mukhopadhya A, Parker R, Ross V, Rowe IA, Srivastava A, Thiagarajan P, Thompson AI, Tomlinson J, Tsochatzis EA, Yeoman A, Alazawi W. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterol Hepatol 2022;7:755-69. [PMID: 35490698 DOI: 10.1016/S2468-1253(22)00061-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
20 Zhao W, Mori H, Tomiga Y, Tanaka K, Perveen R, Mine K, Inadomi C, Yoshioka W, Kubotsu Y, Isoda H, Kuwashiro T, Oeda S, Akiyama T, Zhao Y, Ozaki I, Nagafuchi S, Kawaguchi A, Aishima S, Anzai K, Takahashi H. HSPA8 Single-Nucleotide Polymorphism Is Associated with Serum HSC70 Concentration and Carotid Artery Atherosclerosis in Nonalcoholic Fatty Liver Disease. Genes (Basel) 2022;13:1265. [PMID: 35886046 DOI: 10.3390/genes13071265] [Reference Citation Analysis]
21 López-gonzález ÁA, Altisench Jané B, Masmiquel Comas L, Arroyo Bote S, González San Miguel HM, Ramírez Manent JI. Impact of COVID-19 Lockdown on Non-Alcoholic Fatty Liver Disease and Insulin Resistance in Adults: A before and after Pandemic Lockdown Longitudinal Study. Nutrients 2022;14:2795. [DOI: 10.3390/nu14142795] [Reference Citation Analysis]
22 Muzurović E, Peng CC, Belanger MJ, Sanoudou D, Mikhailidis DP, Mantzoros CS. Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors. Hypertension 2022;79:1319-26. [PMID: 35465684 DOI: 10.1161/HYPERTENSIONAHA.122.17982] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
23 Bilson J, Sethi JK, Byrne CD. Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function. Proc Nutr Soc 2022;81:146-161. [DOI: 10.1017/s0029665121003815] [Reference Citation Analysis]
24 Eriksson MD, Eriksson JG, Korhonen P, Salonen MK, Mikkola TM, Kajantie E, Wasenius NS, von Bonsdorff M, Kautiainen H, Laine MK. Non-melancholic depressive symptoms are associated with above average fat mass index in the Helsinki birth cohort study. Sci Rep 2022;12:6987. [PMID: 35484274 DOI: 10.1038/s41598-022-10592-3] [Reference Citation Analysis]
25 Hartleb M, Mastalerz-Migas A, Kowalski P, Okopień B, Popovic B, Proga K, Cywińska-Durczak B. Healthcare practitioners' diagnostic and treatment practice patterns of nonalcoholic fatty liver disease in Poland: a cross-sectional survey. Eur J Gastroenterol Hepatol 2022;34:426-34. [PMID: 34560694 DOI: 10.1097/MEG.0000000000002288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Wang M, Zhou BG, Zhang Y, Ren XF, Li L, Li B, Ai YW. Association Between Non-alcoholic Fatty Liver Disease and Risk of Stroke: A Systematic Review and Meta-Analysis. Front Cardiovasc Med 2022;9:812030. [PMID: 35345491 DOI: 10.3389/fcvm.2022.812030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Meroni M, Longo M, Lombardi R, Paolini E, Macchi C, Corsini A, Sirtori CR, Fracanzani AL, Ruscica M, Dongiovanni P. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun 2022;6:535-49. [PMID: 34677008 DOI: 10.1002/hep4.1830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
28 Mantovani A, Dalbeni A, Beatrice G, Cappelli D, Gomez-peralta F. Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes. JCM 2022;11:968. [DOI: 10.3390/jcm11040968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
29 Byrne CD, Targher G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. Diabetes Obes Metab 2022;24 Suppl 2:28-43. [PMID: 34324263 DOI: 10.1111/dom.14484] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
30 Alshawsh MA, Alsalahi A, Alshehade SA, Saghir SAM, Ahmeda AF, Al Zarzour RH, Mahmoud AM. A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet. Molecules 2022;27:858. [PMID: 35164140 DOI: 10.3390/molecules27030858] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
31 Younossi ZM, Henry L. Fatty Liver through the Ages- Non-Alcoholic Steatohepatitis (NASH). Endocr Pract 2021:S1530-891X(21)01417-8. [PMID: 34952219 DOI: 10.1016/j.eprac.2021.12.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
32 Pal P, Palui R, Ray S. Heterogeneity of non-alcoholic fatty liver disease: Implications for clinical practice and research activity. World J Hepatol 2021;13:1584-610. [PMID: 34904031 DOI: 10.4254/wjh.v13.i11.1584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
33 Jung I, Lee DY, Lee MY, Kwon H, Rhee EJ, Park CY, Oh KW, Lee WY, Park SW, Park SE. Autonomic Imbalance Increases the Risk for Non-alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:752944. [PMID: 34819920 DOI: 10.3389/fendo.2021.752944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
34 Polyzos SA, Kechagias S, Tsochatzis EA. Review article: non-alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations. Aliment Pharmacol Ther 2021;54:1013-25. [PMID: 34416040 DOI: 10.1111/apt.16575] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
35 Desai MS. Mechanistic insights into the pathophysiology of cirrhotic cardiomyopathy. Anal Biochem 2021;:114388. [PMID: 34587512 DOI: 10.1016/j.ab.2021.114388] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
36 Houttu V, Csader S, Nieuwdorp M, Holleboom AG, Schwab U. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis. Front Nutr 2021;8:716783. [PMID: 34368214 DOI: 10.3389/fnut.2021.716783] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
37 Lastuvkova H, Faradonbeh FA, Schreiberova J, Hroch M, Mokry J, Faistova H, Nova Z, Hyspler R, Igreja Sa IC, Nachtigal P, Stefela A, Pavek P, Micuda S. Atorvastatin Modulates Bile Acid Homeostasis in Mice with Diet-Induced Nonalcoholic Steatohepatitis. Int J Mol Sci 2021;22:6468. [PMID: 34208774 DOI: 10.3390/ijms22126468] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Xu L, Zhou J, Che J, Wang H, Yang W, Zhou W, Zhao H. Mitochondrial DNA enables AIM2 inflammasome activation and hepatocyte pyroptosis in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2021;320:G1034-44. [PMID: 33728991 DOI: 10.1152/ajpgi.00431.2020] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
39 Lonardo A, Arab JP, Arrese M. Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management. Adv Ther 2021;38:2130-58. [PMID: 33829368 DOI: 10.1007/s12325-021-01690-1] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 15.5] [Reference Citation Analysis]
40 Gawlik-Kotelnicka O, Strzelecki D. Probiotics as a Treatment for "Metabolic Depression"? A Rationale for Future Studies. Pharmaceuticals (Basel) 2021;14:384. [PMID: 33924064 DOI: 10.3390/ph14040384] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
41 Abenavoli L, Larussa T, Corea A, Procopio AC, Boccuto L, Dallio M, Federico A, Luzza F. Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease. Nutrients 2021;13:494. [PMID: 33546130 DOI: 10.3390/nu13020494] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
42 Ciardullo S, Zerbini F, Perra S, Muraca E, Cannistraci R, Lauriola M, Grosso P, Lattuada G, Ippoliti G, Mortara A, Manzoni G, Perseghin G. Impact of diabetes on COVID-19-related in-hospital mortality: a retrospective study from Northern Italy. J Endocrinol Invest 2021;44:843-50. [PMID: 32776197 DOI: 10.1007/s40618-020-01382-7] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]